F Boi1,2, F Pani3, P G Calò4,5, M L Lai6, S Mariotti3,7. 1. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. boi@medicina.unica.it. 2. Endocrinology Unit, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, Monserrato, 09042, Cagliari, Italy. boi@medicina.unica.it. 3. Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. 4. Department of Surgical Sciences, University of Cagliari, Cagliari, Italy. 5. Surgery Unit, Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy. 6. Cytomorphology Unit, Azienda Ospedaliero-Universitaria di Cagliari, Cagliari, Italy. 7. Endocrinology Unit, Azienda Ospedaliero-Universitaria di Cagliari, SS 554, Bivio per Sestu, Monserrato, 09042, Cagliari, Italy.
Abstract
BACKGROUND: The association between Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) remains to be elucidated. MATERIALS AND METHODS: A total of 484 HT patients were retrospectively subdivided into two groups: 243 without thyroid nodules, TNs (HTN-) and 241 with TNs (HTN+). Fine-needle aspiration cytology was available in 152 HTN+ patients. This group was compared to a group of 161 patients with nodular goiter (NG) without HT. Finally, 70 HTN+ and 37 NG patients underwent surgery. RESULTS: A very high prevalence of suspicious/malignant cytology (Thy 4-5) at the first diagnosis (38/124; 31%) and during the follow-up (6/28; 22%) was found in HTN+ group. In HTN- group, 22/130 (17%) patients developed TN, but none showed malignant features during the follow-up. HTN+ patients had higher prevalence of Thy 4-5 (44/152 = 28.9%) compared to NG patients (12/161 = 7.4%, p < 0.0001). Increased independent odds ratio (OR) for malignancy was conferred by serum TSH > 1.0 μUI/ml, [OR 1.93, 95% confidence interval (CI) 1.41-2.64, p < 0.0001], male sex (OR 3.44, CI 1.48-8.02, p = 0.004) and HT (OR 3.14; CI 1.08-9.31, p < 0.05). Malignant histology (mostly PTC) was confirmed higher in HTN+ (48/70, 68.6%) compared to NG (15/37, 40.5%; p < 0.05). Higher prevalence of extrathyroidal infiltration (24/48, 50%) and vascular invasion (25/48, 52%) was found in HTN+ vs NG (2/15, 1.3% p < 0.01), (3/16, 1.8% p < 0.05), respectively. CONCLUSIONS: This study confirms higher prevalence of suspicious/malignant cytology and PTC at histology in nodular HT compared to NG, without evidence of malignancy in non-nodular HT patients during the follow-up.
BACKGROUND: The association between Hashimoto's thyroiditis (HT) and papillary thyroid carcinoma (PTC) remains to be elucidated. MATERIALS AND METHODS: A total of 484 HTpatients were retrospectively subdivided into two groups: 243 without thyroid nodules, TNs (HTN-) and 241 with TNs (HTN+). Fine-needle aspiration cytology was available in 152 HTN+ patients. This group was compared to a group of 161 patients with nodular goiter (NG) without HT. Finally, 70 HTN+ and 37 NG patients underwent surgery. RESULTS: A very high prevalence of suspicious/malignant cytology (Thy 4-5) at the first diagnosis (38/124; 31%) and during the follow-up (6/28; 22%) was found in HTN+ group. In HTN- group, 22/130 (17%) patients developed TN, but none showed malignant features during the follow-up. HTN+ patients had higher prevalence of Thy 4-5 (44/152 = 28.9%) compared to NG patients (12/161 = 7.4%, p < 0.0001). Increased independent odds ratio (OR) for malignancy was conferred by serum TSH > 1.0 μUI/ml, [OR 1.93, 95% confidence interval (CI) 1.41-2.64, p < 0.0001], male sex (OR 3.44, CI 1.48-8.02, p = 0.004) and HT (OR 3.14; CI 1.08-9.31, p < 0.05). Malignant histology (mostly PTC) was confirmed higher in HTN+ (48/70, 68.6%) compared to NG (15/37, 40.5%; p < 0.05). Higher prevalence of extrathyroidal infiltration (24/48, 50%) and vascular invasion (25/48, 52%) was found in HTN+ vs NG (2/15, 1.3% p < 0.01), (3/16, 1.8% p < 0.05), respectively. CONCLUSIONS: This study confirms higher prevalence of suspicious/malignant cytology and PTC at histology in nodular HT compared to NG, without evidence of malignancy in non-nodular HTpatients during the follow-up.
Authors: A Loviselli; A Oppo; F Velluzzi; F Atzeni; G L Mastinu; P Farci; G Orgiana; A Balestrieri; P L Cocco; S Mariotti Journal: J Endocrinol Invest Date: 1999-10 Impact factor: 4.256
Authors: E Fiore; T Rago; F Latrofa; M A Provenzale; P Piaggi; A Delitala; M Scutari; F Basolo; G Di Coscio; L Grasso; A Pinchera; P Vitti Journal: Endocr Relat Cancer Date: 2011-07-01 Impact factor: 5.678
Authors: F Boi; L Minerba; M L Lai; B Marziani; B Figus; F Spanu; A Borghero; S Mariotti Journal: J Endocrinol Invest Date: 2012-08-29 Impact factor: 4.256
Authors: K Boelaert; J Horacek; R L Holder; J C Watkinson; M C Sheppard; J A Franklyn Journal: J Clin Endocrinol Metab Date: 2006-07-25 Impact factor: 5.958
Authors: Shawn D Larson; Lindsey N Jackson; Taylor S Riall; Tatsuo Uchida; Robert P Thomas; Suimin Qiu; B Mark Evers Journal: J Am Coll Surg Date: 2007-02-23 Impact factor: 6.113
Authors: G Azizi; J M Keller; M Lewis; K Piper; D Puett; K M Rivenbark; C D Malchoff Journal: Endocr Relat Cancer Date: 2014-09-12 Impact factor: 5.678
Authors: R Rodia; P E Meloni; V Ruggiero; S Mariotti; C Mascia; C Balestrieri; G Serra; M Conti; M Loi; F Pes; S Onali; A Perra; R Littera; F Velluzzi; L Chessa; F Boi Journal: J Endocrinol Invest Date: 2022-09-01 Impact factor: 5.467
Authors: D Słowińska-Klencka; K Wysocka-Konieczna; E Woźniak-Oseła; S Sporny; B Popowicz; J Sopiński; K Kaczka; K Kuzdak; L Pomorski; M Klencki Journal: J Endocrinol Invest Date: 2019-05-10 Impact factor: 4.256
Authors: Federico Cappellacci; Gian Luigi Canu; Maria Letizia Lai; Eleonora Lori; Miriam Biancu; Francesco Boi; Fabio Medas Journal: Front Oncol Date: 2022-07-28 Impact factor: 5.738
Authors: R Rodia; F Pani; G Caocci; G La Nasa; M P Simula; O Mulas; F Velluzzi; A Loviselli; S Mariotti; F Boi Journal: J Endocrinol Invest Date: 2021-07-20 Impact factor: 4.256